KPDS, “Conditionally-approved Tasigna’s clinical trial result must be disclosed”
Korean Pharmacists for Democratic Society(KPDS) announced to make a request for disclosure of the clinical trial result of Novartis’ ‘Tasigna.’
Novartis acquired conditional approval for the Phase 3 clinical trial of the myelogenous leukemia ‘Tasigna’ from the Ministry of Food and Drug Safety(MF...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
